Premium
REAL‐WORLD HEALTHCARE RESOURCE UTILIZATION (HRU) OF CLASSICAL HODGKIN LYMPHOMA (cHL) PATIENTS (PTS) TREATED WITH ANTI‐PD1 CHECKPOINT INHIBITORS IN THE UNITED STATES (US)
Author(s) -
Laliberté F.,
Raut M.,
Duh M.,
Yang X.,
Germain G.,
Sen S.,
MacKnight S.,
Desai K.,
Armand P.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.175_2631
Subject(s) - medicine , pembrolizumab , nivolumab , cancer , immunotherapy